Elamipretide targets cardiolipin within mitochondria and has been studied in several mitochondrial and metabolic disease programs.
Large human trials have generally focused on patients with diagnosed medical conditions rather than healthy adults.
In primary mitochondrial myopathy, a large Phase III study using 40 mg daily did not meet its primary walking or fatigue endpoints.
Elamipretide later received FDA accelerated approval for Barth syndrome, a rare inherited mitochondrial disorder.
No published human trial has established elamipretide for longevity, general mitochondrial support, cognition, exercise recovery, or nonspecific fatigue in healthy adults.
Research also has not established the effectiveness or expected response time of the 5 mg protocol used here.